Press release
Adrenocortical Carcinoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight
Adrenocortical Carcinoma Clinical Trials
"Adrenocortical Carcinoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Adrenocortical Carcinoma Market.
The Adrenocortical Carcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ https://www.delveinsight.com/report-store/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Adrenocortical Carcinoma Pipeline Report:
• Adrenocortical Carcinoma Companies across the globe are diligently working toward developing novel Adrenocortical Carcinoma treatment therapies with a considerable amount of success over the years.
• Adrenocortical Carcinoma companies working in the treatment market are Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, HRA Pharma, Genentech, Cytovation AS, Orphagen Pharmaceuticals and others, are developing therapies for the Adrenocortical Carcinoma treatment
• Emerging Adrenocortical Carcinoma therapies such as Ipilimumab, Relacorilant, LYSODREN (Mitotane), EO2401 + Nivolumab, CyPep-1, OR-449 and others are expected to have a significant impact on the Adrenocortical Carcinoma market in the coming years.
• In January 2023, Orphagen Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) has granted a rare pediatric disease designation (RPDD) to OR-449 for treating pediatric ACC.
Adrenocortical Carcinoma Overview
Adrenocortical carcinoma (ACC) is a rare and aggressive cancer originating in the cortex of the adrenal glands, which are responsible for producing vital hormones such as cortisol, aldosterone, and androgens. ACC accounts for approximately 0.02% of all cancers, with an incidence of 1-2 cases per million people annually. It can occur at any age, but peaks are observed in children under 5 and adults in their 40s-50s.
The presentation of ACC varies depending on whether the tumor is functional (hormone-secreting) or non-functional. Functional tumors often cause hormonal imbalances, leading to symptoms like Cushing's syndrome (weight gain, high blood pressure, and diabetes) or virilization (excess male hormone features in women). Non-functional tumors are often asymptomatic until they grow large, causing abdominal pain or a palpable mass.
Diagnosis involves imaging studies such as CT or MRI, hormonal evaluations, and biopsy in some cases. Surgical resection remains the primary treatment for localized ACC, while advanced cases may require adjuvant therapies like mitotane, chemotherapy, or radiation.
Given its high recurrence rate and poor prognosis, with a 5-year survival rate of 20-45% for advanced stages, early detection and advancements in targeted therapies are critical to improving outcomes for ACC patients.
Get a Free Sample PDF Report to know more about Adrenocortical Carcinoma Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Adrenocortical Carcinoma Route of Administration
Adrenocortical Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
Adrenocortical Carcinoma Molecule Type
Adrenocortical Carcinoma Products have been categorized under various Molecule types, such as
• Monoclonal antibody
• Small molecule
• Peptide
Adrenocortical Carcinoma Pipeline Therapeutics Assessment
• Adrenocortical Carcinoma Assessment by Product Type
• Adrenocortical Carcinoma By Stage and Product Type
• Adrenocortical Carcinoma Assessment by Route of Administration
• Adrenocortical Carcinoma By Stage and Route of Administration
• Adrenocortical Carcinoma Assessment by Molecule Type
• Adrenocortical Carcinoma by Stage and Molecule Type
DelveInsight's Adrenocortical Carcinoma Report covers around 5+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Adrenocortical Carcinoma product details are provided in the report. Download the Adrenocortical Carcinoma pipeline report to learn more about the emerging Adrenocortical Carcinoma therapies- https://www.delveinsight.com/report-store/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Adrenocortical Carcinoma Pipeline Analysis:
The Adrenocortical Carcinoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Adrenocortical Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenocortical Carcinoma Treatment.
• Adrenocortical Carcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Adrenocortical Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenocortical Carcinoma market.
Download Sample PDF Report to know more about Adrenocortical Carcinoma drugs and therapies- https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of Adrenocortical Carcinoma Pipeline Drug Insight
• Coverage: Global
• Adrenocortical Carcinoma companies: Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, HRA Pharma, Genentech. Cytovation AS, Orphagen Pharmaceuticals and others.
• Adrenocortical Carcinoma therapies: Ipilimumab, Relacorilant, LYSODREN (Mitotane), EO2401 + Nivolumab, CyPep-1, OR-449 and others.
• Adrenocortical Carcinoma Therapeutic Assessment: Adrenocortical Carcinoma current marketed and Adrenocortical Carcinoma emerging therapies
• Adrenocortical Carcinoma Market Dynamics: Adrenocortical Carcinoma market drivers and Adrenocortical Carcinoma market barriers
Request for Sample PDF Report for Adrenocortical Carcinoma Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Adrenocortical Carcinoma Report Introduction
2. Adrenocortical Carcinoma Executive Summary
3. Adrenocortical Carcinoma Overview:
4. Adrenocortical Carcinoma- Analytical Perspective In-depth Commercial Assessment
5. Adrenocortical Carcinoma Pipeline Therapeutics
6. Adrenocortical Carcinoma Late Stage Products (Phase II/III)
7. Adrenocortical Carcinoma Mid Stage Products (Phase II)
8. Adrenocortical Carcinoma Early Stage Products (Phase I)
9. Adrenocortical Carcinoma Preclinical Stage Products
10. Adrenocortical Carcinoma Therapeutics Assessment
11. Adrenocortical Carcinoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Adrenocortical Carcinoma Companies
14. Adrenocortical Carcinoma Key Products
15. Adrenocortical Carcinoma Unmet Needs
16 . Adrenocortical Carcinoma Market Drivers and Barriers
17. Adrenocortical Carcinoma Future Perspectives and Conclusion
18. Adrenocortical Carcinoma Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Deep Vein Thrombosis Market: https://www.delveinsight.com/report-store/deep-vein-thrombosis-market
• Dermal Mycosis Market: https://www.delveinsight.com/report-store/dermal-mycosis-market
• Diabetic Nephropathy Market: https://www.delveinsight.com/report-store/diabetic-nephropathy-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Endometriosis Pain Market: https://www.delveinsight.com/report-store/endometriosis-pain-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Facioscapulohumeral Muscular Dystrophy Market: https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Generalized Anxiety Disorder Market: https://www.delveinsight.com/report-store/generalized-anxiety-disorder-gad-market
• Generalized Pustular Psoriasis Market: https://www.delveinsight.com/report-store/generalized-pustular-psoriasis-market
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Healthcare Portfolio Management Services: https://www.delveinsight.com/consulting/pharmaceutical-portfolio-management-solutions
• Hemorrhagic Cystitis Market: https://www.delveinsight.com/report-store/hemorrhagic-cystitis-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market
• Human Papillomavirus Positive Cancer Market: https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/hyperhidrosis-market
• Immunologic Deficiency Syndrome Market: https://www.delveinsight.com/report-store/immunologic-deficiency-syndrome-market
• Menorrhalgia Market: https://www.delveinsight.com/report-store/menorrhalgia-market
• Metachromatic Leukodystrophy Market Research Report: https://www.delveinsight.com/report-store/metachromatic-leukodystrophy-mld-market
• Metastatic Bone Pain Market: https://www.delveinsight.com/report-store/metastatic-bone-pain-market
• Myelofibrosis Market: https://www.delveinsight.com/report-store/myelofibrosis-mf-market
• Ncfb Market: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Adrenocortical Carcinoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight here
News-ID: 3774089 • Views: …
More Releases from DelveInsight Business Research
HPK1 Inhibitors Market Outlook 2034: Comprehensive 7MM Forecast, Emerging Pipeli …
DelveInsight has released its latest report, "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2034," delivering an in-depth analysis of the rapidly evolving HPK1 inhibitor market. The report offers a comprehensive overview of the epidemiology, drug uptake, treatment landscape, competitive intelligence, and market dynamics shaping the outlook of HPK1 inhibitors across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To know more about the HPK1 Inhibitor…
Hypersomnia Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Prog …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hypersomnia pipeline constitutes 3+ key companies continuously working towards developing 4+ Hypersomnia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Hypersomnia Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypersomnia Market.
The Hypersomnia Pipeline report embraces in-depth…
Diabetic Kidney Disease Pipeline 2026: Therapies Under Investigation, Clinical T …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Kidney Disease pipeline constitutes key companies continuously working towards developing Diabetic Kidney Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Diabetic Kidney Disease Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Kidney Disease Market.
…
Pompe Disease Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and K …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Pompe Disease pipeline constitutes 15+ key companies continuously working towards developing 20+ Pompe Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Pompe Disease Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pompe Disease Market.
The Pompe Disease…
More Releases for Adrenocortical
Adrenocortical Carcinoma Treatment Market Diagnostic Improvements and Evolving T …
The Adrenocortical Carcinoma (ACC) Treatment Market is growing steadily as improvements in diagnostic imaging, surgical oncology, and targeted therapies enhance the management of this rare but aggressive endocrine malignancy. ACC often presents late and requires multimodal treatment including surgery, adrenalectomy, mitotane therapy, chemotherapy, and emerging immunotherapies. Rising clinical awareness, improved diagnostic accuracy, and expansion of cancer centers specializing in rare tumors are fueling demand for effective ACC treatments.
Download Full PDF…
Adrenocortical Hormones API Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs, For External Use Drugs, Inhalation Drugs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global Adrenocortical Hormones API Market is valued at US$ 2.24 Billion…
Adrenocortical Carcinoma Drugs Market Overview: Growth, Share, Value, Size, and …
The global Adrenocortical Carcinoma Drugs market is projected to reach approximately USD 0.85 billion by 2033, growing at a compound annual growth rate (CAGR) of around 7.2% from 2025 to 2033.
Adrenocortical Carcinoma Drugs Market Overview
The global Adrenocortical Carcinoma (ACC) drugs market is experiencing growth, driven by the increasing incidence of this rare endocrine malignancy and advancements in therapeutic approaches. ACC is characterized by aggressive tumor behavior and limited treatment options,…
Adrenocortical Hormones API Market Survey Detailed Analysis and Forecast 2024-20 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs, For External Use Drugs, Inhalation Drugs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global Adrenocortical Hormones API Market is valued at US$ 2.24 Billion…
Adrenocortical Carcinoma Treatment: Challenges, Advances, and Market Dynamics
Adrenocortical carcinoma (ACC) is a rare and aggressive form of cancer originating in the adrenal cortex, the outer layer of the adrenal glands. These glands, located above the kidneys, are responsible for producing hormones that regulate a variety of bodily functions, such as metabolism, blood pressure, and immune response. ACC is often diagnosed at an advanced stage due to its asymptomatic early course, and treatment options are limited. In this…
Adrenocortical Hormones API Market to Witness Robust Expansion by 2025
LP INFORMATION recently released a research report on the Adrenocortical Hormones API market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global Adrenocortical Hormones APImarket by key players, product type, applications and regions,etc.
The main objective of this market research is to help the readers understand the structure of Adrenocortical Hormones APImarket, market definition, overview, industry opportunities…
